SGLT2i delays c-Myc-induced HCC progression via targeting mTOR
Our study highlights EMPA's potential as a therapeutic agent in delaying the development and progression of HCC.
Authors
- Lin Tian (ORCID: https://orcid.org/0009-0003-7944-7154)
- Huiling Rao (ORCID: https://orcid.org/0000-0003-3332-1479)
- Jie Jia (ORCID: https://orcid.org/0009-0007-0172-4659)
- Wanrong Li (ORCID: https://orcid.org/0000-0003-4645-2726)
- Weixing Du
- Lei You (ORCID: https://orcid.org/0000-0002-1649-803X)
- Zhengpeng Qiu
- Juan Yu
- Jin Xie (ORCID: https://orcid.org/0000-0002-1761-4397)
- Shan Li (ORCID: https://orcid.org/0000-0001-5882-2240)
- Jing Ke (ORCID: https://orcid.org/0000-0002-9181-6042)
- Zhixin Liu (ORCID: https://orcid.org/0000-0001-7253-7438)
- Xiaoyan Qu (ORCID: https://orcid.org/0000-0002-8276-1692)
- D. Liu
- Xiaotong An
Institutions
- Hubei University of Medicine (CN)
- Army Medical University (CN)
- Hubei University of Chinese Medicine (CN)
- Taihe Hospital (CN)
- People's Hospital of Shiyan (CN)
Publication Details
- Journal
- Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Published
- 2025-03-18
- DOI
- https://doi.org/10.1016/j.bbadis.2025.167805
- Citations
- 4
- Primary Topic
- Peptidase Inhibition and Analysis
- Type
- article
- Field-Weighted Citation Impact
- 4.18